CHRS
Coherus OncologyFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
8
U.S. public peers
Grade Position
Below peers
vs peer average
CHRS vs peer average
32/100
CHRS vs. peer average (F vs. D)
Grade spread
B 1 · C 2 · D 2 · F 3
Graded peers loaded
Coverage
8 graded
100% of tracked
Peer overview
AKBA is the first available peer comparator.
Same sector: Pharmaceuticals, Biotechnology & Life Sciences · Cap $157.09M
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
CHRS
Coherus Oncology
AKBA
Akebia Therapeutics
Grade
F
B
Momentum
18
16
Value
41
53
Sentiment
-
71
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Constructive
Grade position vs AKBA
CHRS / AKBA
Grade Position
Below peers
CHRS vs. peer average (F vs. D)
32/100
Momentum
18
CHRSValue
41
AKBASentiment
-
-Rotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs CHRS
AKBA is the first peer returned for this comparison set.